Clinical trials: Sleep Disorder; Insomnia Type
Insomnia, Insomnia Type; Sleep Disorder
Evaluation Of The Diamine Oxidase Supplementation Effect In Patients With Insomnia Symptoms
Considering the high prevalence of DAO enzyme deficiency in patients referring insomnia symptoms, it would be plausible that the appearance of insomnia symptoms were explained by the DAO enzyme deficiency.
- Trial name
- DAO-SLEEP-2023 (NCT07027943)
- Testing
- DAO supplement
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- AB Biotek
Sleep Disturbance, Insomnia
The CANabidiol Use for RElief of Short Term Insomnia
This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.
- Conditions
- Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient
- Trial name
- CANREST (NCT05253417)
- Testing
- 50 mg Cannabidiol (CBD), 100 mg Cannabidiol (CBD)
- Where
- 2 sites in Australia
- Volunteers
- 208 people
- Sponsor
- Bod Australia
Insomnia Type; Sleep Disorder
Sleep and Cardiovascular Health in Adolescence
Insomnia is a prevalent and under-recognized disorder in adolescence, particularly in girls, with long-term repercussions for mental and physical health.
- Trial name
- NCT03727906
- Testing
- No pre-sleep arousal manipulation, pre-sleep arousal down-regulation, pre-sleep arousal up-regulation
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- SRI International
Diabetes Mellitus, Type 2, Insomnia
A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia
Objective - Type 2 uncontrolled diabetic patients often have low endogenous melatonin and suffer from sleep disorders. The effect of a prolonged-release melatonin (PRM) formulation on glucose lipid metabolism and sleep is studied…
- Trial name
- NCT00869128
- Testing
- Circadin
- Volunteers
- 36 people
- Sponsor
- Neurim Pharmaceuticals Ltd.